Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017032 | 0.95 | HRH3 (0.49) | HRH3KDM4EMEN1KMT2A | |
| SCHEMBL5023005 | 0.88 | HRH3 (0.59) | HRH3KDM4ECYP2D6CYP3A4MEN1 | |
| SCHEMBL4504510 | 0.87 | HRH3 (0.54) | HRH3CYP2D6CYP3A4SLC5A7MEN1 | |
| SCHEMBL5023152 | 0.84 | HRH3 (0.64) | HRH3 | |
| SCHEMBL5017097 | 0.83 | HRH3 (0.53) | HRH3KDM4ECYP2D6CYP3A4MEN1 | |
| SCHEMBL5017065 | 0.83 | HRH3 (0.66) | HRH3 | |
| SCHEMBL5017158 | 0.80 | HRH3 (0.63) | HRH3 | |
| SCHEMBL5023588 | 0.80 | HRH3 (0.56) | HRH3MEN1KMT2A | |
| SCHEMBL5024383 | 0.80 | HRH3 (0.57) | HRH3 | |
| SCHEMBL1379104 | 0.79 | HRH3 (0.68) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761519-B1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7361682-B2 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HRH3, HRH4, ADRB1 | HRH3 1/4885KDM4E 1001/4885CYP2D6 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.